Nortriptyline - Pain (Neuropathic)

You are here : Home > Formulary Search > Nortriptyline - Pain (Neuropathic)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary

Formulations :

Not Specified

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

NFD1

SPC

Restrictions / Comments :

Documentation

Guidelines (Local)

Neuropathic Pain Guidelines for Primary Care - Oct 20

Guidelines (National)

NICE Clinical guideline [CG173] : Neuropathic pain in adults: pharmacological management in non-specialist settings

PAD Profile

ChemicalSubstance :

Nortriptyline

Indication :

Pain (Neuropathic)

Group Name :

Keywords :

neuropathic pain, Tricyclic antidepressants, TCAs, tricyclics, PHN, post herpetic neuralgia, postherpetic neuralgia, diabetic neuropathy

Brand Names Include :

Allegron

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Nortriptyline is used to treat.

Depression

Other Drugs

Below are listed other drugs that are used to treat Pain (Neuropathic).

Committee Recommendations (2)

07 Oct 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Area Prescribing Committee recommends that nortriptyline for use in neuropathic pain should remain as unsuitable for prescribing and agreed to assign it a NON-FORMULARY status for this indication

There appears to be no evidence available to recommend this off label treatment. It is not recommended in NICE guidance (CG173) "Neuropathic pain in adults: pharmacological management in non-specialist settings ".
Amitriptyline is the only tricyclic recommended by NICE. It recommends a switch to another class of drug if amitriptyline is not tolerated or contra-indicated

See guidelines below

03 Jun 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.